R a tolman (21 resultados)

Condición: As New. Unread book in perfect condition.

Condición: New.

PAPERBACK. Condición: VG. 5TH PRINTING. FRANKLIN SLY AND TOLMAN R. REAMER (ilustrador).

Soft cover. Condición: New. Language:Chinese.Author:AI DE HUA TUO ER MAN (Edward Chace Tolman) LI WEI YI.Binding:Soft cover.Publisher:Peking University Press Pub. Date: 2010-12-01.

Condición: New.

Condición: New.

Condición: New. In English.

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - It has been ten years since the National Hormone and Pituitary Program (then called the National Pituitary Agency) sponsored a symposium on human growth hormone (hGH). Numerous advances have occurred during this period. This book does not attempt to summarize past achievements. Rather, it deals with the contemporary issues in hGH research. A discussion of the present state of the art, of necessity, includes a review of the past. Some of the topics herein discussed include the following: 1. Growth hormone releasing factor (GRF). In 1973, the growth hormone inhibitory factor (somatostatin) had recently been discovered. The search for a releasing factor in humans led to its discovery not in the pituitary but in a pancreatic tumor that secreted growth hormone. The advances are discussed in this book. The current hope is that GRF will eventually become an effective therapeutic agent for idiopathic hypopituitarism in childhood and adolescence. 2. Biosynthesis of hGR by recombinant DNA technology. Current advances are discussed. Although hGH is not yet an approved drug, it will eventually become one. This will broaden our horizons in terms of hGH effectiveness in disorders other than hypopituitary dwarfism. The current experience with this type of hGH in both the Vnited States and Europe is reviewed by several authors.…

Condición: New. pp. 680.

Paperback. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condición: As New. Unread book in perfect condition.

Hardcover. Condición: Good -. Binding tight; interior clean other than gift inscription (dated 1909) in pencil on ffep. Red and cream half-bound boards with gilt lettering and design; heavy wear and bumping at corners. A collection of stories, poems, and activities for children by various authors. Illustrated in black and white. Full-color frontis. Unpaginated, but approx. 94pp. Baynes, Hiram; Hambridge, Jay; Goodwin, C. L. (ilustrador). …

Venlo Van Spijk 1993, In linnen gebonden met stofomslag. Hardcover. 26 x26 cm. Met illustraties in kleur en z/w. 184 pag. - UITSTEKEND EXEMPLAAR [Art / Dutch artist [Nederlandse Kunstenaars] Beeldhouwen / Sculpting ].

[Lancaster], American Institute of Physics, 1939. Royal8vo. Bound in contemporary full red cloth with gilt lettering to spine. Entire volume of "The Physical Review", Volume 55, Second Series, January 1 - June 15, 1939. "Development Department" in small gilt lettering to lower part of spine. A very fine and clean copy. [Bethe:] Pp. 434-456. [Oppenheimer & Volkoff:] Pp. 374-381. [Entire volume: 1300 pp.]. First printing of "ENERGY PRODUCTION IN STARS", Hans Bethe's seminal Nobel Prize winning paper on neucleosynthesis. It was the first time an astrophysical subject was recognized by the Nobel Committee. Bethe's work on nuclear reactions led him to discover the reactions that supply the energy in stars. In this paper, Bethe shows that "the most important source of energy in ordinary stars is the reactions of carbon and nitrogen with protons" (Bethe, Energy Production in Stars). Bethe began by analyzing the different possibilities for reactions by which hydrogen is fused into helium. He showed two processes to be the sources of energy generation capable of keeping stars hot. The first, the proton-proton chain, is the dominant energy source in stars with masses up to about the mass of the Sun. The second, the carbon-nitrogen-oxygen cycle, is the most important in more massive stars. "ON MASSIVE NEUTRON CORES" and NEUTRON STARS AND THE TOLMAN-OPPENHEIMER-VOLKOV LIMIT, two landmark papers which "for the first time laid a general relativistic theory of stellar structure" (Pais, Subtle is the Lord), thereby proving Einstein wrong in his conclusion that no star could collapse indefinitely.In the paper they addressed the question that Landau's paper, and also Oppenheimer and Serber's, had failed to consider: what is the maximum mass for stable neutron-star? This paper applied Tolman's method to calculate the gravitational equilibrium of a neutron star and predict the conditions under which it will continue collapsing into a black hole (the Tolman-Oppenheimer-Volkov Limit). The issue contain several other papers of interest: 1. Tolman, Richard. "Static Solutions of Einstein's Field Equations for Spheres of Fluid" - This paper developed a method for applying Einstein's field equations to static spheres of fluid in such a manner as to facilitate the development of exact solutions using known analytic functions)" Jenkins and Segre's "Quadratic Zeeman Effect" and "Zeeman Effect of the Forbidden Lines of Potassium" .2. Gamow & Teller. "On the Origin of Great Nebulae". 3. Seaborg & Segre. "Nuclear Isomerism in Element 43" 4. Gentner & Segre. "Appendix on the Calibration of the Ionization Chamber". 5. Bethe. "On the Absence of Polarization in Electron Scattering" & "Meson Theory of Nuclear Forces.".…

Condición: new. Questo è un articolo print on demand.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -It has been ten years since the National Hormone and Pituitary Program (then called the National Pituitary Agency) sponsored a symposium on human growth hormone (hGH). Numerous advances have occurred during this period. This book does not attempt to summarize past achievements. Rather, it deals with the contemporary issues in hGH research. A discussion of the present state of the art, of necessity, includes a review of the past. Some of the topics herein discussed include the following: 1. Growth hormone releasing factor (GRF). In 1973, the growth hormone inhibitory factor (somatostatin) had recently been discovered. The search for a releasing factor in humans led to its discovery not in the pituitary but in a pancreatic tumor that secreted growth hormone. The advances are discussed in this book. The current hope is that GRF will eventually become an effective therapeutic agent for idiopathic hypopituitarism in childhood and adolescence. 2. Biosynthesis of hGR by recombinant DNA technology. Current advances are discussed. Although hGH is not yet an approved drug, it will eventually become one. This will broaden our horizons in terms of hGH effectiveness in disorders other than hypopituitary dwarfism. The current experience with this type of hGH in both the Vnited States and Europe is reviewed by several authors. 680 pp. Englisch.…

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. It has been ten years since the National Hormone and Pituitary Program (then called the National Pituitary Agency) sponsored a symposium on human growth hormone (hGH). Numerous advances have occurred during this period. This book does not attempt to summari.…

Paperback. Condición: new. Paperback. It has been ten years since the National Hormone and Pituitary Program (then called the National Pituitary Agency) sponsored a symposium on human growth hormone (hGH). Numerous advances have occurred during this period. This book does not attempt to summarize past achievements. Rather, it deals with the contemporary issues in hGH research. A discussion of the present state of the art, of necessity, includes a review of the past. Some of the topics herein discussed include the following: 1. Growth hormone releasing factor (GRF). In 1973, the growth hormone inhibitory factor (somatostatin) had recently been discovered. The search for a releasing factor in humans led to its discovery not in the pituitary but in a pancreatic tumor that secreted growth hormone. The advances are discussed in this book. The current hope is that GRF will eventually become an effective therapeutic agent for idiopathic hypopituitarism in childhood and adolescence. 2. Biosynthesis of hGR by recombinant DNA technology. Current advances are discussed. Although hGH is not yet an approved drug, it will eventually become one. This will broaden our horizons in terms of hGH effectiveness in disorders other than hypopituitary dwarfism. The current experience with this type of hGH in both the Vnited States and Europe is reviewed by several authors. It has been ten years since the National Hormone and Pituitary Program (then called the National Pituitary Agency) sponsored a symposium on human growth hormone (hGH). The search for a releasing factor in humans led to its discovery not in the pituitary but in a pancreatic tumor that secreted growth hormone. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -It has been ten years since the National Hormone and Pituitary Program (then called the National Pituitary Agency) sponsored a symposium on human growth hormone (hGH). Numerous advances have occurred during this period. This book does not attempt to summarize past achievements. Rather, it deals with the contemporary issues in hGH research. A discussion of the present state of the art, of necessity, includes a review of the past. Some of the topics herein discussed include the following: 1. Growth hormone releasing factor (GRF). In 1973, the growth hormone inhibitory factor (somatostatin) had recently been discovered. The search for a releasing factor in humans led to its discovery not in the pituitary but in a pancreatic tumor that secreted growth hormone. The advances are discussed in this book. The current hope is that GRF will eventually become an effective therapeutic agent for idiopathic hypopituitarism in childhood and adolescence. 2. Biosynthesis of hGR by recombinant DNA technology. Current advances are discussed. Although hGH is not yet an approved drug, it will eventually become one. This will broaden our horizons in terms of hGH effectiveness in disorders other than hypopituitary dwarfism. The current experience with this type of hGH in both the Vnited States and Europe is reviewed by several authors.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 680 pp. Englisch.…

Condición: New. Print on Demand pp. 680 66:B&W 7 x 10 in or 254 x 178 mm Perfect Bound on White w/Gloss Lam.

Condición: New. PRINT ON DEMAND pp. 680.